These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 560248)
1. Antimitotic and antitubulin activity of the tumor inhibitor steganacin. Wang RW; Rebhum LI; Kupchan SM Cancer Res; 1977 Sep; 37(9):3071-9. PubMed ID: 560248 [TBL] [Abstract][Full Text] [Related]
2. Steganacin: an inhibitor of HeLa cell growth and microtubule assembly in vitro. Schiff PB; Kende AS; Horwitz SB Biochem Biophys Res Commun; 1978 Nov; 85(2):737-46. PubMed ID: 736931 [No Abstract] [Full Text] [Related]
3. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Bai R; Cichacz ZA; Herald CL; Pettit GR; Hamel E Mol Pharmacol; 1993 Oct; 44(4):757-66. PubMed ID: 8232226 [TBL] [Abstract][Full Text] [Related]
4. Antimitotic antifungal compound benomyl inhibits brain microtubule polymerization and dynamics and cancer cell proliferation at mitosis, by binding to a novel site in tubulin. Gupta K; Bishop J; Peck A; Brown J; Wilson L; Panda D Biochemistry; 2004 Jun; 43(21):6645-55. PubMed ID: 15157098 [TBL] [Abstract][Full Text] [Related]
5. 3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells. Jiang JD; Davis AS; Middleton K; Ling YH; Perez-Soler R; Holland JF; Bekesi JG Cancer Res; 1998 Dec; 58(23):5389-95. PubMed ID: 9850070 [TBL] [Abstract][Full Text] [Related]
6. Methylenedioxy-benzopyran analogs of podophyllotoxin, a new synthetic class of antimitotic agents that inhibit tubulin polymerization. Batra JK; Kang GJ; Jurd L; Hamel E Biochem Pharmacol; 1988 Jul; 37(13):2595-602. PubMed ID: 3390218 [TBL] [Abstract][Full Text] [Related]
7. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo. Perchellet EM; Ladesich JB; Magill MJ; Chen Y; Hua DH; Perchellet JP Anticancer Drugs; 1999 Jun; 10(5):489-504. PubMed ID: 10477169 [TBL] [Abstract][Full Text] [Related]
8. Structure-function studies with derivatives of 6-benzyl-1,3-benzodioxole, a new class of synthetic compounds which inhibit tubulin polymerization and mitosis. Batra JK; Jurd L; Hamel E Mol Pharmacol; 1985 Jan; 27(1):94-102. PubMed ID: 3965931 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the interaction of the marine cyanobacterial natural product curacin A with the colchicine site of tubulin and initial structure-activity studies with analogues. Blokhin AV; Yoo HD; Geralds RS; Nagle DG; Gerwick WH; Hamel E Mol Pharmacol; 1995 Sep; 48(3):523-31. PubMed ID: 7565634 [TBL] [Abstract][Full Text] [Related]
10. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674 [TBL] [Abstract][Full Text] [Related]
11. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin. Bhattacharyya B; Panda D; Gupta S; Banerjee M Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966 [TBL] [Abstract][Full Text] [Related]
12. Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. McGown AT; Fox BW Anticancer Drug Des; 1989 Mar; 3(4):249-54. PubMed ID: 2930627 [TBL] [Abstract][Full Text] [Related]
13. Oxalone and lactone moieties of podophyllotoxin exhibit properties of both the B and C rings of colchicine in its binding with tubulin. Gupta S; Das L; Datta AB; Poddar A; Janik ME; Bhattacharyya B Biochemistry; 2006 May; 45(20):6467-75. PubMed ID: 16700557 [TBL] [Abstract][Full Text] [Related]
14. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Tahir SK; Han EK; Credo B; Jae HS; Pietenpol JA; Scatena CD; Wu-Wong JR; Frost D; Sham H; Rosenberg SH; Ng SC Cancer Res; 2001 Jul; 61(14):5480-5. PubMed ID: 11454695 [TBL] [Abstract][Full Text] [Related]
15. Correlation of tubulin-binding and antitumor activities of podophyllotoxin analogs. Kelleher JK Cancer Treat Rep; 1978 Oct; 62(10):1443-7. PubMed ID: 101303 [TBL] [Abstract][Full Text] [Related]
16. Antimitotic activity of the potent tumor inhibitor maytansine. Remillard S; Rebhun LI; Howie GA; Kupchan SM Science; 1975 Sep; 189(4207):1002-5. PubMed ID: 1241159 [TBL] [Abstract][Full Text] [Related]
17. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024 [TBL] [Abstract][Full Text] [Related]
18. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Yoshimatsu K; Yamaguchi A; Yoshino H; Koyanagi N; Kitoh K Cancer Res; 1997 Aug; 57(15):3208-13. PubMed ID: 9242451 [TBL] [Abstract][Full Text] [Related]
19. Cornigerine, a potent antimitotic Colchicum alkaloid of unusual structure. Interactions with tubulin. Hamel E; Ho HH; Kang GJ; Lin CM Biochem Pharmacol; 1988 Jun; 37(12):2445-9. PubMed ID: 3390207 [TBL] [Abstract][Full Text] [Related]
20. Low potency of taxol at microtubule minus ends: implications for its antimitotic and therapeutic mechanism. Derry WB; Wilson L; Jordan MA Cancer Res; 1998 Mar; 58(6):1177-84. PubMed ID: 9515803 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]